# Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma

> **NCT01154452** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 78 (actual)

## Conditions studied

- Adult Alveolar Soft Part Sarcoma
- Adult Angiosarcoma
- Adult Desmoplastic Small Round Cell Tumor
- Adult Epithelioid Hemangioendothelioma
- Adult Epithelioid Sarcoma
- Adult Extraskeletal Myxoid Chondrosarcoma
- Adult Extraskeletal Osteosarcoma
- Adult Fibrosarcoma
- Adult Leiomyosarcoma
- Adult Liposarcoma
- Adult Malignant Mesenchymoma
- Adult Malignant Peripheral Nerve Sheath Tumor
- Adult Rhabdomyosarcoma
- Adult Synovial Sarcoma
- Adult Unclassified Pleomorphic Sarcoma
- Chondrosarcoma
- Clear Cell Sarcoma of the Kidney
- Conjunctival Kaposi Sarcoma
- Dermatofibrosarcoma Protuberans
- Gastrointestinal Stromal Tumor
- Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Metastatic Osteosarcoma
- Ovarian Sarcoma
- Recurrent Adult Soft Tissue Sarcoma
- Recurrent Adult Unclassified Pleomorphic Sarcoma of Bone
- Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Recurrent Kaposi Sarcoma
- Recurrent Osteosarcoma
- Recurrent Uterine Corpus Sarcoma
- Small Intestine Leiomyosarcoma
- Stage III Adult Soft Tissue Sarcoma
- Stage III Uterine Sarcoma
- Stage IV Adult Soft Tissue Sarcoma
- Stage IV Uterine Sarcoma
- Unclassified Pleomorphic Sarcoma of Bone

## Interventions

- **DRUG:** Gamma-Secretase Inhibitor RO4929097
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study
- **DRUG:** Vismodegib

## Key facts

- **NCT ID:** NCT01154452
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2015-02
- **Final completion:** 2015-02
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2018-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01154452

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01154452, "Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01154452. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*